- Home
- KNRX vs ERNA Comparison
KNRX vs ERNA Comparison
Compare KNRX & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNRX | ERNA |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 5.3M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KNRX | ERNA |
|---|---|---|
| Price | $0.18 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 32.0K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.84 |
| 52 Week High | $3.45 | $71.50 |
Technical Indicators
Market Signals| Indicator | KNRX | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 43.29 | 30.06 |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.49 | $4.72 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 21.18 | 19.38 |
Price Performance
Historical ComparisonAbout KNRX KNOREX LTD. Class A Ordinary Shares
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.